Dr. Ritter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
505 S Nolen Dr
Southlake, TX 76092Phone+1 817-424-1525Fax+1 817-424-3491
Education & Training
University of Texas Southwestern Medical CenterFellowship, Gastroenterology, 1990 - 1993- University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1987 - 1990
University of Texas Southwestern Medical SchoolClass of 1987
Certifications & Licensure
TX State Medical License 1988 - 2026
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Clinical Trials
- A Study of CDPATH™ to Help Manage and Treat Crohn's Disease Start of enrollment: 2021 Jun 25
Roles: Principal Investigator
- A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) Start of enrollment: 2024 Jun 12
Roles: Principal Investigator
- A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease Start of enrollment: 2024 Apr 18
Roles: Principal Investigator
Publications & Presentations
PubMed
- Appropriate cleaning reduces potential risk of spore transmission from patients with Clostridioides difficile infection treated in outpatient infusion centers.Claudia P Schroeder, Richard L Hengel, Ramesh V Nathan, Timothy E Ritter, Engels N Obi
Anaerobe. 2022-10-01 - 26 citationsMANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases.Wayne J G Hellstrom, Radboud J E M Dolhain, Timothy E Ritter, Timothy R Watkins, Sarah J Arterburn
Advances in Therapy. 2022-07-01 - 39 citationsEtrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3...Severine Vermeire, Peter L. Lakatos, Timothy Ritter, Stephen B. Hanauer, Brian Bressler
The Lancet. Gastroenterology & Hepatology. 2021-11-16
Press Mentions
Expert: Fatty Liver Disease Is the Next Healthcare EpidemicAugust 19th, 2019
More Real-World Data and New Analyses of Data for REBYOTA® (Fecal Microbiota, Live – Jslm) Presented at IDWeek 2023October 15th, 2023- U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s DiseaseApril 19th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
